Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP.
Yan QinHaizhu ChenPeng LiuChanggong ZhangJianliang YangLin GuiXiaohui HeLiqiang ZhouShengyu ZhouShiyu JiangHongxin JiangYuan-Kai ShiPublished in: Cancer biology & medicine (2021)
This study showed that DLBCL patients treated with R-CHOP, BCL2 alterations, especially BCL2GA/AMP and TP53 mutations were significantly associated with inferior outcomes, which were independent of the IPI. The novel prognostic models we proposed predicted outcomes for DLBCL patients treated with R-CHOP, but further validation of the prognostic models is still warranted.